4d Pharma PLC Annual Report and Notice of AGM

4D pharma plc (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today announced that the Annual Report and Accounts for the year to 31 December 2017 and Notice of the Company’s Annual General Meeting (“AGM”) have been posted to shareholders.

An electronic copy of each of the Annual Report and Accounts and the Notice of AGM is available on the Company’s website, www.4dpharmaplc.com.

The AGM will be held on Monday 21 May 2018 at 11 a.m. at the Gridiron Building, 1 Pancras Square, London N1C 4AG.

 

Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect.  All of 4D’s live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has completed a phase I study in Irritable Bowel Syndrome and has recently completed dosing in a phase I study in Paediatric Crohn’s Disease.  It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    4d Pharma Plc

    More articles like this

    4d Pharma Plc

    People with fibromyalgia have different gut bacteria

    A study that compared women with and without fibromyalgia has, for the first time, linked gut bacteria to the long-lasting disease and its main symptoms. Researchers in Canada identified 19 species of gut bacteria that were present in

    4d Pharma Plc

    Findings link gut bacteria and Fibromyalgia

    Fibromyalgia affects 2-4 percent of the population and has no known cure. Symptoms include fatigue, impaired sleep, and cognitive difficulties, but the disease is most clearly characterized by widespread chronic pain. As reported in the journal Pain, approximately 20

    4d Pharma Plc

    Gut bacteria: The surprising impact of viruses

    The microbiome plays a vital role in health. A recent study has investigated how viruses that kill gut bacteria influence these microbes. The findings make an already complicated picture much more so. The microbiome is both fascinating and

    4d Pharma Plc

    4D pharma plc Presents MRx0518 combination study at ASCO

    4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announced the presentation of a poster detailing its Phase I/II clinical study of MRx0518 combined with KEYTRUDA® in patients with solid tumours who